Incidence and prevention of skeletal‐related events in multiple myeloma patients: A population‐based real‐world experience

Novel treatments in multiple myeloma (MM) could influence the incidence of skeletal‐related events (SREs). We aimed to examine the incidence of SRE and the preventive use of osteoclast inhibitors (OIs) in a cohort of MM patients in the era of modern treatment. In this real‐world retrospective study,...

Full description

Saved in:
Bibliographic Details
Published in:EJHaem 2024-08, Vol.5 (4), p.669-676
Main Authors: Røra, Marie, Solberg, Margrete Skretting, Moore, Kari Lenita Falck, Slørdahl, Tobias S.
Format: Article
Language:English
Subjects:
Bisphosphonates
Calcium and Vitamin D
Collaboration
Creatinine
denosumab
Diagnosis
Dosage
Epidemiology
Fractures
Hematology
Hypercalcemia
Hypocalcemia
Kidney diseases
Mandible
Multiple myeloma
osteoclast inhibitors
Osteonecrosis
osteonecrosis of the jaw
Osteoporosis
Patients
Proteins
skeletal‐related events
Spinal cord
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Novel treatments in multiple myeloma (MM) could influence the incidence of skeletal‐related events (SREs). We aimed to examine the incidence of SRE and the preventive use of osteoclast inhibitors (OIs) in a cohort of MM patients in the era of modern treatment. In this real‐world retrospective study, we included 199 patients with a diagnosis of MM between January 1, 2010, and December 31, 2019, with follow‐up at St. Olavs University Hospital. Data was extracted from The Myeloma Registry of Central Norway. SREs occurred in 46% of patients at baseline and 55.8% during follow‐up. Excluding baseline SREs, the incidence rate was 29 (95% confidence interval: 26–33) per 100 person years. 48% experienced > 1 SRE. The incidence of SREs was highest at baseline followed by a gradual increase in each subsequent line of treatment. The first two years after diagnosis 80% received bisphosphonates (BPs). The proportion of recommended dosage was 46%. Only two cases (1.2%) of symptomatic hypocalcemia and one case (0.6%) of osteonecrosis of the jaw were identified. SREs are still a common problem in an era of novel treatment. Cumulative dosage of BPs was lower than recommended, and treatment with BPs was safe in this population.
ISSN:2688-6146
2688-6146
DOI:10.1002/jha2.928